Hereditary Gingival Overgrowth In Epileptic Patient: A Case Report
Gingival overgrowth (GO) is the abnormal enlargement of gingiva which may be caused due to different etiological factors such as inflammation, drug or inherited (hereditary) gingival fibromatosis (HGF), Gingival fibromatosis is a rare and heterogeneous group of disorders that develop as slowly progressive, local or diffuse enlargements within marginal and attached gingiva or interdental papilla. Unlike DIGO which usually occurs as a generalized diffuse enlargement, HGF is characterized by a slow, progressive growth of the gingival tissue. Gingival fibromatosis may be familial or idiopathic. Treatments vary according to the type of overgrowth and the extent of disease progression, thus, scaling of teeth is sufficient in mild cases, while in severe cases surgical intervention is required. Risk of recurrence of HGF exists. This article presents case report of gingival hypermatosis with distinctive facies, and diagnosis and treatment of the disease.
2. American Academy of Periodontology. Glossary of Periodontal Terms. 4th ed. Chicago, IL: American Academy of Periodontology; 2001.
3. Gurgel BC, Morais CR, Rocha-Neto PC, Dantas EM, Pinto LP, Costa AD. Phenytoin-induced gingival overgrowth management with periodontal treatment. Brazilian dental journal. 2015 Jan;26:39-43.
4. Bharti V, Bansal C. Drug-induced gingival overgrowth: The nemesis of gingiva unravelled. Journal of Indian Society of Periodontology. 2013 Mar;17(2):182.
5. Gawron K, Bartyzel KL, Potempa J and Gajewska M. Gingival fibromatosis: clinical, molecular and therapeutic issues. Orphanet Journal of Rare Diseases (2016) 11:9
6. Vipin B, Chhaya B Drug-induced gingival over growth: The nemesis of gingiva unraveled. J Indian Soc Periodontol. 2013; 17: 182-187.
7. Bhowmick SK, Gidvani VK, Retting KR. Hereditary gingival fibromatosis and growth retardation. Endocr Pract. 2001;7: 383-387
8. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol .1996;23:165-75.
9. Kimball OP. The treatment of epilepsy with sodium diphenyl hydantoinate. JAMA 1939;112:1244-5.
10. Majola MP, McFadyen ML, Connolly C, Nair YP, Govender M, Laher MH. Factors influencing phenytoin-induced gingival enlargement. J Clin Periodontol 2000;27:506-512.
11. Kamali F, McLaughlin WS, Ball DE, Seymour RA. The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth. J CIin Periodontol. 1999;26:802-805.
12. Moffitt ML, Bencivenni D, Cohen RE. Drug-induced gingival enlargement: an overview. Compend Contin Educ Dent. 2013;34:330-336.
13. Costa AL, Yasuda CL, Shibasaki W, Nahás-Scocate AC, de Freitas CF, Carvalho PE et al. The association between periodontal disease and seizure severity in refractory epilepsy patients. Seizure. 2014 Mar 1;23(3):227-30.
14. Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. Journal of pharmaceutical health care and sciences. 2017 Dec;3(1):1-1.
15. Gawron K, Łazarz-Bartyzel K, Potempa J, Chomyszyn-Gajewska M. Gingival fibromatosis: clinical, molecular and therapeutic issues. Orphanet journal of rare diseases. 2016 Dec;11(1):1-4.
16. Bansal A, Narang S, Sowmya K, Sehgal N. Treatment and two year follow up of a patient with hereditary gingival fibromatosis. J Indian Soc Periodontol.2011; 15: 406-409
17. Ye X, Shi L, Yin W, Meng L, Wang QK, Bian Z. Further evidence of genetic heterogeneity segregating with hereditary gingival fibromatosis. J Clin Periodontol. 2009;36:627-33.